{"gene":"TXNRD1","run_date":"2026-04-28T21:43:00","timeline":{"discoveries":[{"year":2023,"finding":"RSL3 and ML162, commonly used as GPX4 inhibitors to study ferroptosis, are in fact potent inhibitors of TXNRD1 and lack capacity to inhibit recombinant selenoprotein GPX4 enzymatic activity; other known TXNRD1 inhibitors (auranofin, TRi-1, TRi-2) also induce cell death but through ferroptosis-independent mechanisms.","method":"In vitro enzymatic activity assays with recombinant GPX4 and TXNRD1, cell death assays with ferrostatin-1","journal":"Redox biology","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with recombinant proteins, multiple orthogonal assays","pmids":["37087975"],"is_preprint":false},{"year":2024,"finding":"TXNRD1 drives the senescence-associated secretory phenotype (SASP) and inflammaging through the cGAS-STING innate immune pathway independently of its enzymatic activity; TXNRD1 localizes to cytoplasmic chromatin fragments, physically interacts with cGAS in a senescence-dependent manner, enhances cGAS enzymatic activity, and is required for SASP-mediated tumor-promoting and immune surveillance functions in vivo.","method":"Co-immunoprecipitation, subcellular fractionation, cGAS activity assays, mouse models with TXNRD1 inhibitors selective for enzymatic vs. cGAS-interaction functions, loss-of-function studies","journal":"Nature aging","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP, functional enzymatic assays, multiple in vivo models, orthogonal inhibitors distinguishing enzymatic vs. protein-interaction roles","pmids":["38267705"],"is_preprint":false},{"year":2014,"finding":"Selenocysteine (Sec)-containing TrxR1 is absolutely required for self-sufficient growth of mouse embryonic fibroblasts under high-glucose conditions due to its essential role in eliminating glucose-derived H2O2; Sec-devoid TrxR1 variants cannot rescue this function.","method":"Txnrd1 knockout MEFs reconstituted with wild-type vs. Sec-devoid TrxR1 variants, H2O2 measurement, cell death assays","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 1 — genetic reconstitution with mutagenesis in defined cell system","pmids":["24853413"],"is_preprint":false},{"year":2011,"finding":"In vivo hepatocyte DNA replication requires either glutathione (GSH) or at least one functional allele of Txnrd1; complete loss of both pathways (Txnrd1-null hepatocytes + BSO-mediated GSH depletion) severely impairs hepatocyte replication, establishing that TrxR1 and GSH independently support ribonucleotide reductase electron donation in vivo.","method":"Genetic mouse models (Txnrd1 conditional knockout), BSO treatment, replicative index measurement, TrxR activity assays","journal":"Free radical biology & medicine","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis in vivo with defined mechanistic readout, controlled genetic backgrounds","pmids":["22198266"],"is_preprint":false},{"year":2013,"finding":"Hepatocyte-specific disruption of Txnrd1 causes a metabolic switch repressing lipogenic genes, engorging periportal hepatocytes with glycogen, upregulating glutathione biosynthesis, UDP-glucuronate machinery, glutathione-S-transferases, UDP-glucuronyl-transferases, and xenobiotic exporters; NAPQI (from acetaminophen) directly inactivates TrxR1, yet Txnrd1-null livers are resistant to APAP hepatotoxicity due to constitutively enhanced GSH and glucuronidation systems.","method":"Hepatocyte-specific Txnrd1 conditional knockout mice, metabolomic profiling, APAP hepatotoxicity challenge, in vitro NAPQI-TrxR1 inactivation assay","journal":"Free radical biology & medicine","confidence":"High","confidence_rationale":"Tier 1–2 — genetic KO with metabolomics, in vitro enzymatic inactivation, in vivo toxicology challenge","pmids":["23743293"],"is_preprint":false},{"year":2009,"finding":"RITA binds TrxR1 non-covalently and inhibits its activity in vitro and in cancer cells in a p53-dependent manner; RITA also induces a ~130 kDa stable covalently linked TrxR1 dimer and increases ROS specifically in cancer cells but not normal fibroblasts, in a p53-dependent fashion.","method":"In vitro TrxR1 activity assay, cell-based TrxR activity measurement, ROS detection, Western blot for TrxR1 dimer","journal":"Cell cycle","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro + cellular assays, p53-dependence shown, but mechanistic detail on non-covalent binding is limited","pmids":["19838062"],"is_preprint":false},{"year":2013,"finding":"TrxR1 inhibition (via auranofin or siRNA) combined with AKT inhibition (MK2206) induces synthetic lethality in NSCLC cells through KEAP1/NRF2-dependent ROS accumulation and JNK activation; wild-type KEAP1 function is required for this synthetic lethality.","method":"Genome-wide siRNA library screen, combinatorial drug treatment, KEAP1 mutant cell lines, ROS measurement, in vivo xenograft","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — genetic screen plus mechanistic follow-up with genetic controls, replicated in vivo","pmids":["23824739"],"is_preprint":false},{"year":2020,"finding":"TrxR1 inhibition by irreversible inhibitors induces oxidation of Prx2 and STAT3, which blocks STAT3-dependent transcription; previously identified STAT3 inhibitors also inhibit TrxR1, and TrxR1 inhibitors block STAT3-dependent transcriptional activity through redox-mediated STAT3 oxidation.","method":"Luciferase reporter assays, TrxR1 inhibitor profiling, oxidation state analysis of Prx2 and STAT3, target engagement studies","journal":"Science advances","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic link between TrxR1 inhibition and STAT3 oxidation established with multiple orthogonal approaches","pmids":["32219156"],"is_preprint":false},{"year":2011,"finding":"In C. elegans, TRXR-1 (selenoprotein thioredoxin reductase) functions together with GSR-1 glutathione reductase to reduce disulfide bonds in the cuticle during molting; selenocysteine-to-cysteine TRXR-1 mutants fail to rescue molting defects, demonstrating strict selenocysteine dependence; exogenous reduced glutathione can substitute to induce apolysis.","method":"C. elegans genetic knockouts/mutants, selenocysteine-to-cysteine mutant rescue experiments, SELB-1 mutants (selenocysteine incorporation factor), exogenous GSH treatment, cuticle oxidation state analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 — genetic reconstitution with selenocysteine mutagenesis in C. elegans ortholog, multiple genetic and biochemical approaches","pmids":["21199936"],"is_preprint":false},{"year":2009,"finding":"The TXNRD1_v3 splice variant (carrying an N-terminal glutaredoxin domain) forms dynamic cytoplasmic filaments and induces filopodia formation when overexpressed; both filament formation and filopodia are dependent on the glutaredoxin domain; filopodia but not filaments require actin polymerization.","method":"Live cell imaging, truncation mutants, actin polymerization inhibitors, overexpression in cell lines","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 — direct live imaging with domain-mapping mutants, clean cellular phenotype","pmids":["19654027"],"is_preprint":false},{"year":2013,"finding":"TXNRD1_v3 membrane targeting is mediated by myristoylation and palmitoylation of its N-terminal MGC motif, directing it specifically to membrane rafts; v3-mediated filopodia induction is independent of redox-active Cys residues but dependent on membrane raft targeting.","method":"Site-directed mutagenesis of MGC motif, lipid fractionation, cholera toxin B co-localization, truncated mutant analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis of lipidation sites combined with fractionation and functional filopodia readout","pmids":["23413027"],"is_preprint":false},{"year":2006,"finding":"Diverse gold compounds (auranofin, gold sodium thiomalate, sodium aurothiosulfate, triphenyl phosphine gold chloride, gold acetate) all inhibit TrxR1 at nanomolar concentrations; Au(I)-phosphine compounds are most potent; ligand configuration rather than gold oxidation state determines inhibitory potency.","method":"Ex vivo TrxR1 activity assay with purified rat TrxR1, IC50 determination, comparison with cellular mitochondrial toxicity","journal":"Toxicology in vitro","confidence":"Medium","confidence_rationale":"Tier 1 — in vitro enzymatic assay with structure-activity analysis, single study","pmids":["16510263"],"is_preprint":false},{"year":2018,"finding":"Manumycin A irreversibly inhibits TrxR1 (IC50 272 nM with preincubation) by forming a Michael adduct with the selenocysteine residue in the C-terminal redox center, converting TrxR1 into a SecTRAP that uses NADPH to reduce oxygen to superoxide.","method":"In vitro TrxR1 activity assay with/without preincubation, time-dependence analysis, covalent modification evidence, superoxide production assay","journal":"ACS medicinal chemistry letters","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with mechanistic characterization of covalent selenocysteine modification","pmids":["29670693"],"is_preprint":false},{"year":2017,"finding":"miR-23a and miR-23b directly bind the 3' UTR of TrxR1 mRNA, repressing its expression during early C2C12 myoblast differentiation; TrxR1 depletion promotes myogenic gene expression (myogenin, Myf5 upregulation; Cyclin D1 decrease), while TrxR1 overexpression delays myogenesis.","method":"3' UTR luciferase reporter assay, miRNA mimic/inhibitor transfection, TrxR1 KD and OE in C2C12 cells, myogenic marker expression analysis","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — direct 3' UTR binding confirmed by reporter assay, functional rescue experiments, defined cellular phenotype","pmids":["28775321"],"is_preprint":false},{"year":2015,"finding":"Trx1/TrxR1 system regulates survival of post-selected CD69+ double-positive thymocytes by suppressing ASK1, JNK, and p38 MAPK phosphorylation and limiting Bim upregulation; TrxR1 inhibition specifically reduces post-selected DP thymocytes both in vitro and in vivo.","method":"TrxR1 inhibitor treatment in vitro and in vivo, Western blot for ASK1/JNK/p38 phosphorylation, flow cytometry for thymocyte subsets, Bim expression analysis","journal":"Immunology and cell biology","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro and in vivo pharmacological inhibition with defined signaling pathway readout","pmids":["25753394"],"is_preprint":false},{"year":2022,"finding":"TXNRD1 attenuates the interaction between Trx1 and PTEN, resulting in accelerated PTEN degradation and consequent Akt/mTOR pathway activation, promoting HCC cell mobility and metastasis; USF2 is a transcriptional suppressor that directly binds two E-box sites in the TXNRD1 promoter to repress its expression.","method":"Co-IP (Trx1-PTEN interaction), siRNA knockdown, overexpression studies, ChIP/dual-luciferase for USF2-TXNRD1 promoter interaction, in vitro and in vivo xenograft models","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP demonstrating Trx1-PTEN interaction modulated by TXNRD1, promoter-binding confirmed by luciferase, functional in vivo validation","pmids":["36319631"],"is_preprint":false},{"year":2017,"finding":"A homozygous TXNRD1 mutation (p.Pro190Leu) reduces enzyme activity to 16–34% of controls in patient fibroblasts and skeletal muscle; in vitro kinetic analysis of recombinant mutant TXNRD1 shows 30–40% lower kcat/Se values; reduced enzyme abundance was confirmed by 75Se labeling; patient fibroblasts show reduced resistance to H2O2 challenge.","method":"75Se labeling, Western blot, in vitro kinetic analysis of recombinant mutant protein, enzymatic activity assays in patient-derived cells, exome sequencing","journal":"Free radical biology & medicine","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinetic analysis of recombinant mutant protein combined with patient-derived tissue enzymatic studies and Se-labeling","pmids":["28232204"],"is_preprint":false},{"year":2023,"finding":"During RANKL-induced osteoclastogenesis, NFATc1 transcriptionally upregulates SLC7A11 (cystine transporter); TXNRD1 inhibition reduces intracellular disulfide reduction rate, causing cystine accumulation and disulfidptosis selectively in osteoclast precursors; this cell death is blocked by SLC7A11 inhibitors but not by ferroptosis, apoptosis, necroptosis, or autophagy inhibitors.","method":"NFATc1 transcriptional reporter assays, pharmacological TXNRD1 inhibition, SLC7A11 inhibitors, selective inhibitors of multiple death pathways, OVX mouse model in vivo","journal":"Redox biology","confidence":"High","confidence_rationale":"Tier 2 — mechanistic dissection with multiple selective inhibitors and in vivo model, NFATc1-SLC7A11 transcriptional link confirmed","pmids":["37148740"],"is_preprint":false},{"year":2022,"finding":"The RX1 probe selectively targets mammalian TrxR1 via a cyclic selenenylsulfide that exploits TrxR1's unique selenolthiol chemistry; probe selectivity validated by TrxR1 knockout, selenium starvation, knock-in, and chemical inhibitors; used for quantitative live-cell high-throughput screening of TrxR1 inhibitors.","method":"Genetic KO, selenium starvation, knock-in complementation, chemical inhibitors, live-cell fluorescence imaging, high-throughput screening","journal":"Chem","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal genetic and chemical validation methods for probe selectivity","pmids":["35936029"],"is_preprint":false},{"year":2019,"finding":"TrxR1 and Gsr together maintain antioxidant defense in mouse liver; TrxR1-null livers develop threefold fewer DEN-induced tumors compared to wild-type, suggesting TrxR1 promotes carcinogen-induced cancer initiation; elevated oxidative stress (TrxR1/Gsr double-null) correlates with increased malignancy independently of Nrf2 expression within tumors.","method":"Conditional knockout mouse models (TrxR1-null, Gsr-null, double-null), DEN carcinogenesis model, DNA damage measurement, metabolomics, tumor burden quantification","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic mouse models with defined carcinogenesis challenge and metabolomic profiling","pmids":["31097586"],"is_preprint":false},{"year":2023,"finding":"Nrf2 positively regulates TXNRD1 protein expression, shown by co-immunoprecipitation and Western blotting; deferoxamine activates nuclear translocation of Nrf2 in hippocampal neurons and thereby upregulates TXNRD1 to suppress ferroptosis and inflammation after subarachnoid hemorrhage.","method":"Co-immunoprecipitation, Western blotting, Nrf2 pathway inhibitor (ML385), in vivo SAH mouse model, in vitro FIN56 ferroptosis model","journal":"Molecular neurobiology","confidence":"Medium","confidence_rationale":"Tier 2–3 — Co-IP for Nrf2-TXNRD1 regulation, pathway inhibitor used to confirm, in vivo model","pmids":["37676391"],"is_preprint":false},{"year":2024,"finding":"lncRNA CARD8-AS1 acts as a scaffold to facilitate the interaction between TXNRD1 and E3 ubiquitin ligase TRIM25, promoting TXNRD1 degradation through the ubiquitin-proteasome pathway; TXNRD1 overexpression reverses the tumor-suppressive effects of CARD8-AS1 in lung adenocarcinoma.","method":"RNA pull-down, Co-IP, ubiquitination assays, rescue experiments with TXNRD1 overexpression, in vitro and in vivo functional studies","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2–3 — Co-IP and ubiquitination assay for TRIM25-TXNRD1 interaction, functional rescue, single lab","pmids":["38153696"],"is_preprint":false},{"year":2025,"finding":"Glaucocalyxin A (GLA) selectively forms covalent bonds with Cys173 of PRDX1 and Cys59, Cys64, Cys497, and Sec498 of TXNRD1 (with reactivity order Sec498 > Cys59 > Cys497 > Cys64), inhibiting their enzymatic activities, disrupting redox homeostasis, and triggering autophagy-mediated ferroptosis in NSCLC cells.","method":"Activity-based protein profiling (ABPP), covalent binding site identification by mass spectrometry, computational chemistry, in vitro enzymatic activity assays, in vivo xenograft","journal":"Phytomedicine","confidence":"Medium","confidence_rationale":"Tier 1–2 — ABPP target identification with site-specific covalent modification confirmed by MS and computational analysis","pmids":["41016297"],"is_preprint":false},{"year":2023,"finding":"Elovanoid-N34 directly modulates TXNRD1 activity by binding to TXNRD1 isoforms 2 or 3 (identified by limited proteolysis screening), inducing structural changes at the FAD interface domain; ELV-N34 decreases both membrane and cytosolic TXNRD1 activity, revealing distinct subcellular localizations of the enzyme.","method":"Limited proteolysis (LiP) mass spectrometry screening, TXNRD1 silencing to confirm isoform specificity, TXNRD1 activity assays in membrane and cytosolic fractions","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 1–2 — LiP-MS for direct target identification, isoform-specific silencing, subcellular fractionation activity assays","pmids":["38086796"],"is_preprint":false},{"year":2025,"finding":"ROS-triggered prodrug 5u releases active compound 6a, which covalently binds to Cys475 and Sec498 sites on TXNRD1, inhibiting its activity, disrupting redox homeostasis, and causing apoptosis and ferroptosis in NSCLC cells.","method":"Covalent binding site identification, in vitro TrxR1 activity assay, cell death mechanism assays (apoptosis/ferroptosis markers), in vivo xenograft and organoid models","journal":"Journal of medicinal chemistry","confidence":"Medium","confidence_rationale":"Tier 1 — in vitro reconstitution with site-specific covalent modification, functional cell death assays, single study","pmids":["39869029"],"is_preprint":false},{"year":2024,"finding":"Butein irreversibly inhibits recombinant TXNRD1 in a time-dependent manner by modifying catalytic Cys residues, identified by TrxR1 mutant variants and LC-MS; cellular ROS accumulation results and reversal of cisplatin resistance is achieved through TXNRD1 inhibition.","method":"In vitro enzymatic assay with recombinant TXNRD1, TXNRD1 Cys mutant variants, LC-MS covalent modification identification, cellular ROS assays, cisplatin-resistant cell line studies","journal":"Biological trace element research","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with mutagenesis and MS-confirmed covalent modification of catalytic residues","pmids":["39141196"],"is_preprint":false},{"year":2023,"finding":"Thimerosal competitively and reversibly inhibits TrxR1 with an IC50 of 24.08 nM, identified via a high-throughput screening assay based on enzyme kinetics.","method":"Enzyme kinetics-based high-throughput screening, IC50 determination, competitive inhibition mode analysis, cellular ROS assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 1 — in vitro enzymatic kinetics with defined inhibition mode, single study","pmids":["36780763"],"is_preprint":false},{"year":2023,"finding":"TXNRD1 knockdown in oscillatory shear stress (Oss)-treated human aortic endothelial cells inhibits their proliferation, migration, and tube formation by activating the eNOS/apoptosis pathway; L-NAME (eNOS inhibitor) reverses these effects, placing eNOS downstream of TXNRD1 in this context.","method":"TXNRD1 siRNA knockdown, Oss shear stress bioreactor, L-NAME pharmacological inhibition, proliferation/migration/tube formation assays, flow cytometry for apoptosis","journal":"Biochimica et biophysica acta. Molecular cell research","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KD with pharmacological epistasis defining eNOS as downstream effector, defined cellular phenotype","pmids":["36754152"],"is_preprint":false},{"year":2025,"finding":"TrxR1/2 inhibition by isowalsuranolide (Hdy-7) leads to ROS accumulation that activates p53 and subsequent lysosomal biogenesis via TFEB/TFE3 nuclear translocation; knockdown of TrxR1/2 phenocopies this effect; pharmacological or genetic inhibition of autophagy prevents Hdy-7-induced cell death, indicating autophagic cell death downstream of TrxR1/2 inhibition.","method":"TrxR1/2 knockdown, ROS scavenger (NAC), p53 knockdown, SESN2 knockdown, TFEB/TFE3 nuclear translocation assays, autophagy inhibition, in vitro TrxR activity assays","journal":"Science China. Life sciences","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KD combined with multiple pathway-specific inhibitors and nuclear translocation assays, mechanistic pathway defined","pmids":["40059270"],"is_preprint":false}],"current_model":"TXNRD1 is a cytosolic selenoprotein thioredoxin reductase whose uniquely reactive selenocysteine (Sec) at the C-terminal redox center is the primary target for diverse electrophilic and gold-based inhibitors; it maintains redox homeostasis by reducing thioredoxin (Trx1) and eliminating glucose-derived H2O2 in a strictly Sec-dependent manner, supports hepatocyte proliferation and a metabolic program in liver, drives the SASP/inflammaging through a non-enzymatic interaction with cGAS to enhance innate immune signaling, regulates Nrf2/KEAP1-dependent antioxidant transcription, modulates PTEN stability via Trx1, controls T-cell development via ASK1-JNK/p38 suppression, and its splice variant v3 localizes to membrane rafts via N-acylation to induce filopodia through its glutaredoxin domain independently of redox activity."},"narrative":{"teleology":[{"year":2006,"claim":"The question of how gold-based therapeutics target TrxR1 was resolved by showing that diverse gold compounds inhibit TrxR1 at nanomolar concentrations, with Au(I)-phosphine ligand configuration—not oxidation state—determining potency, establishing TrxR1 as a pharmacologically druggable selenoenzyme.","evidence":"In vitro IC50 determination with purified rat TrxR1 and structurally diverse gold compounds","pmids":["16510263"],"confidence":"Medium","gaps":["Binding site on TrxR1 not mapped","Selectivity over TrxR2 not assessed","In vivo target engagement not demonstrated"]},{"year":2009,"claim":"The identification of the TXNRD1_v3 splice variant revealed that its N-terminal glutaredoxin domain drives filopodia formation and cytoplasmic filament assembly independently of canonical TrxR1 reductase function, establishing a non-canonical cytoskeletal role for a TrxR1 isoform.","evidence":"Live-cell imaging of overexpressed v3 with truncation and domain-deletion mutants, actin polymerization inhibitors in cell lines","pmids":["19654027"],"confidence":"Medium","gaps":["Endogenous expression levels and physiological relevance of v3 unclear","Binding partners mediating filopodia unknown","Redox independence based on domain deletion, not active-site mutagenesis"]},{"year":2011,"claim":"Genetic epistasis in vivo demonstrated that TrxR1 and glutathione constitute two parallel electron-supply pathways for hepatocyte DNA replication—likely converging on ribonucleotide reductase—resolving how cells tolerate loss of either pathway alone.","evidence":"Txnrd1 conditional knockout mice with BSO-mediated GSH depletion, replicative index measurement in hepatocytes","pmids":["22198266"],"confidence":"High","gaps":["Direct measurement of ribonucleotide reductase activity in double-depleted hepatocytes not performed","Contribution of other reductases not excluded"]},{"year":2011,"claim":"The strict requirement for selenocysteine in TrxR catalysis was established across species: Sec-to-Cys mutants of C. elegans TRXR-1 fail to rescue molting, and Sec-devoid TrxR1 cannot eliminate glucose-derived H₂O₂ in mouse embryonic fibroblasts, proving that Sec is not a dispensable catalytic residue.","evidence":"Sec-to-Cys mutant rescue in C. elegans molting and in Txnrd1-null MEFs under high glucose; H₂O₂ measurement","pmids":["21199936","24853413"],"confidence":"High","gaps":["Structural basis for why Sec is required (redox potential, pKa) not resolved in these studies","Whether any biological context allows Sec-devoid activity remains open"]},{"year":2013,"claim":"Hepatocyte-specific Txnrd1 loss triggered a compensatory metabolic switch—upregulating GSH biosynthesis, glucuronidation, and xenobiotic export while repressing lipogenesis—revealing TrxR1 as a metabolic rheostat whose absence paradoxically confers resistance to acetaminophen hepatotoxicity.","evidence":"Hepatocyte-specific Txnrd1 conditional knockout mice with metabolomic profiling and APAP challenge; NAPQI shown to directly inactivate TrxR1 in vitro","pmids":["23743293"],"confidence":"High","gaps":["Transcriptional mediators of the metabolic switch not fully identified","Whether Nrf2 drives all compensatory changes unclear"]},{"year":2013,"claim":"Membrane raft targeting of TXNRD1_v3 was shown to require N-terminal myristoylation and palmitoylation of the MGC motif, and filopodia induction depended on raft localization but not on redox-active cysteines, separating the structural/signaling role of v3 from enzymatic catalysis.","evidence":"Site-directed mutagenesis of MGC lipidation motif, lipid raft fractionation, cholera toxin B co-localization, filopodia quantification","pmids":["23413027"],"confidence":"High","gaps":["Downstream signaling partners at membrane rafts unidentified","In vivo relevance of v3-driven filopodia not tested"]},{"year":2013,"claim":"A synthetic lethal interaction between TrxR1 inhibition and AKT inhibition was discovered in NSCLC, dependent on intact KEAP1 function, linking TrxR1 to the KEAP1/NRF2 antioxidant axis and JNK activation as a cell death mechanism.","evidence":"Genome-wide siRNA screen combined with MK2206, KEAP1-mutant cell lines, ROS quantification, xenograft validation","pmids":["23824739"],"confidence":"Medium","gaps":["Whether TrxR1 directly modifies KEAP1 or acts indirectly via ROS not distinguished","Generalizability beyond NSCLC not tested"]},{"year":2015,"claim":"TrxR1 was placed upstream of the ASK1-JNK/p38-Bim apoptotic cascade in thymocytes, explaining how the Trx1/TrxR1 system supports survival of post-selected double-positive thymocytes during T-cell development.","evidence":"TrxR1 pharmacological inhibition in vitro and in vivo with phospho-ASK1/JNK/p38 and Bim readouts, flow cytometry of thymocyte subsets","pmids":["25753394"],"confidence":"Medium","gaps":["Genetic TrxR1 deletion in thymocytes not performed","Whether Trx1 oxidation state directly controls ASK1 binding not shown in this system"]},{"year":2017,"claim":"A human homozygous TXNRD1 mutation (p.Pro190Leu) was shown to reduce enzymatic activity to 16–34% of normal in patient tissues, with recombinant mutant protein showing reduced kcat, establishing TXNRD1 as a disease gene for a selenoprotein deficiency disorder.","evidence":"Patient-derived fibroblast and muscle enzymatic assays, ⁷⁵Se labeling, recombinant mutant kinetic analysis, exome sequencing","pmids":["28232204"],"confidence":"High","gaps":["Full clinical spectrum not defined","Whether residual activity is from the mutant or compensatory pathways not resolved","Only one family reported"]},{"year":2018,"claim":"The mechanism by which electrophilic inhibitors convert TrxR1 into a pro-oxidant was elucidated: manumycin A forms a Michael adduct specifically at the C-terminal Sec residue, generating a SecTRAP that channels NADPH electrons to O₂ to produce superoxide.","evidence":"In vitro preincubation kinetics, time-dependent irreversible inhibition, covalent modification evidence, superoxide production assay with purified TrxR1","pmids":["29670693"],"confidence":"High","gaps":["Crystal structure of the SecTRAP not resolved","In vivo superoxide generation from SecTRAP not quantified"]},{"year":2019,"claim":"TrxR1 was shown to promote carcinogen-induced hepatocellular cancer initiation in vivo, as TrxR1-null livers developed threefold fewer DEN-induced tumors, while combined TrxR1/Gsr loss increased tumor malignancy independently of Nrf2, revealing opposing roles of moderate vs. excessive oxidative stress in tumorigenesis.","evidence":"Conditional TrxR1-null, Gsr-null, and double-null mouse liver models with DEN carcinogenesis, DNA damage and metabolomic profiling","pmids":["31097586"],"confidence":"High","gaps":["Mechanism by which TrxR1 promotes initiation (DNA damage tolerance vs. proliferation support) not fully defined","Cell-autonomous vs. microenvironmental effects not separated"]},{"year":2020,"claim":"TrxR1 was identified as an upstream regulator of STAT3 redox state: its inhibition causes Prx2 and STAT3 oxidation, blocking STAT3-dependent transcription and explaining off-target mechanisms of several 'STAT3 inhibitors'.","evidence":"Luciferase reporter assays, TrxR1 inhibitor profiling, Prx2/STAT3 oxidation state analysis","pmids":["32219156"],"confidence":"Medium","gaps":["Whether TrxR1→Trx1→Prx2→STAT3 is the sole pathway not excluded","Direct Trx1-STAT3 interaction not demonstrated"]},{"year":2022,"claim":"TXNRD1 was shown to modulate PTEN stability by competing with PTEN for Trx1 binding; high TXNRD1 expression accelerates PTEN degradation and activates Akt/mTOR signaling, and USF2 directly represses TXNRD1 transcription via E-box elements.","evidence":"Co-IP for Trx1-PTEN interaction ± TXNRD1, ChIP/dual-luciferase for USF2-TXNRD1 promoter binding, xenograft models","pmids":["36319631"],"confidence":"Medium","gaps":["Mechanism of PTEN degradation (ubiquitin ligase identity) not identified","Whether this occurs in non-HCC contexts unknown","Reciprocal Co-IP for TXNRD1-Trx1 competition not fully shown"]},{"year":2023,"claim":"The widely used 'GPX4 inhibitors' RSL3 and ML162 were demonstrated to potently inhibit TXNRD1 without inhibiting recombinant GPX4, fundamentally reframing the ferroptosis field's tool compound specificity and indicating that many attributed GPX4-dependent effects may reflect TXNRD1 inhibition.","evidence":"In vitro enzymatic assays with recombinant GPX4 and TXNRD1, ferrostatin-1 rescue experiments","pmids":["37087975"],"confidence":"High","gaps":["In-cell target engagement ratio (GPX4 vs. TXNRD1) not quantified","Whether downstream ferroptotic phenotypes are TXNRD1-dependent not fully resolved"]},{"year":2023,"claim":"TXNRD1 inhibition was linked to a novel cell death modality—disulfidptosis—in osteoclast precursors: NFATc1-driven SLC7A11 upregulation during osteoclastogenesis creates dependence on TXNRD1 for intracellular disulfide reduction, and TXNRD1 inhibition causes lethal cystine accumulation.","evidence":"Pharmacological TXNRD1 inhibition with selective death pathway inhibitors, SLC7A11 inhibitor rescue, NFATc1 transcriptional assays, OVX mouse model","pmids":["37148740"],"confidence":"High","gaps":["Whether TXNRD1 directly reduces cystine or acts via Trx1 not resolved","Generalizability of disulfidptosis mechanism to other SLC7A11-high cell types not tested"]},{"year":2024,"claim":"A non-enzymatic, protein-interaction function of TXNRD1 was discovered: TXNRD1 localizes to cytoplasmic chromatin fragments in senescent cells, physically interacts with cGAS, enhances cGAS enzymatic activity, and drives the SASP and inflammaging through cGAS-STING signaling independently of TrxR1 reductase activity.","evidence":"Reciprocal Co-IP, subcellular fractionation, cGAS activity assays, enzymatic-vs-interaction-selective inhibitors, multiple mouse models","pmids":["38267705"],"confidence":"High","gaps":["Structural basis for TXNRD1-cGAS interaction not resolved","Which TXNRD1 domain mediates cGAS binding unknown","Whether this interaction occurs in non-senescent inflammatory contexts not tested"]},{"year":2024,"claim":"TXNRD1 protein stability was shown to be regulated by TRIM25-mediated ubiquitination scaffolded by lncRNA CARD8-AS1, adding a post-translational degradation mechanism to the regulatory landscape of TXNRD1 abundance.","evidence":"RNA pull-down, Co-IP, ubiquitination assays, rescue with TXNRD1 overexpression in lung adenocarcinoma models","pmids":["38153696"],"confidence":"Medium","gaps":["TRIM25 ubiquitination sites on TXNRD1 not mapped","Whether this mechanism operates outside lung adenocarcinoma not tested","Single-lab finding awaiting independent confirmation"]},{"year":null,"claim":"Key unresolved questions include: the structural basis for TXNRD1's non-enzymatic interaction with cGAS; whether the SecTRAP pro-oxidant form of TrxR1 has physiological signaling roles; how TXNRD1 isoform-specific functions (v3 membrane raft signaling, cytosolic redox catalysis) are coordinated in vivo; and whether TXNRD1 loss-of-function mutations cause a broader clinical spectrum beyond the single reported family.","evidence":"","pmids":[],"confidence":"Low","gaps":["No crystal structure of TXNRD1-cGAS complex","SecTRAP physiological relevance untested","Full disease spectrum of TXNRD1 deficiency undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[2,3,4,8,12,16,18,25]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[1,15]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[2,23]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[10,23]}],"pathway":[{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[2,4,6,7,17,19]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[3]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[1,14]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[17,24,28]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[6,7,15]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[4]}],"complexes":[],"partners":["TXN","CGAS","PTEN","TRIM25","PRDX2","GSR"],"other_free_text":[]},"mechanistic_narrative":"TXNRD1 encodes cytosolic thioredoxin reductase 1 (TrxR1), a selenoprotein oxidoreductase that serves as a central node in cellular redox homeostasis by reducing thioredoxin (Trx1) and eliminating reactive oxygen species in a selenocysteine (Sec)-dependent manner [PMID:24853413, PMID:22198266]. Its C-terminal Sec residue is the primary target of diverse electrophilic and gold-based inhibitors that form covalent adducts, converting the enzyme into a pro-oxidant SecTRAP [PMID:29670693, PMID:16510263, PMID:39141196]; TrxR1 and glutathione reductase constitute parallel, partially redundant reductive pathways that together supply electrons to ribonucleotide reductase for DNA synthesis and maintain hepatic metabolic programming [PMID:22198266, PMID:23743293, PMID:31097586]. Beyond its enzymatic role, TXNRD1 physically interacts with cGAS on cytoplasmic chromatin fragments to enhance cGAS enzymatic activity and drive the senescence-associated secretory phenotype independently of its reductase activity [PMID:38267705], and the TXNRD1_v3 splice variant localizes to membrane rafts via N-terminal myristoylation/palmitoylation to induce filopodia through its glutaredoxin domain independently of redox catalysis [PMID:23413027, PMID:19654027]. A homozygous TXNRD1 missense mutation (p.Pro190Leu) that reduces enzymatic activity to 16–34% of normal causes a generalized selenoprotein deficiency disorder [PMID:28232204]."},"prefetch_data":{"uniprot":{"accession":"Q16881","full_name":"Thioredoxin reductase 1, cytoplasmic","aliases":["Gene associated with retinoic and interferon-induced mortality 12 protein","GRIM-12","Gene associated with retinoic and IFN-induced mortality 12 protein","KM-102-derived reductase-like factor","Peroxidase TXNRD1","Thioredoxin reductase TR1"],"length_aa":649,"mass_kda":70.9,"function":"Reduces disulfide protein thioredoxin (Trx) to its dithiol-containing form (PubMed:8577704). Homodimeric flavoprotein involved in the regulation of cellular redox reactions, growth and differentiation. A selenocysteine residue at the C-terminal active site is essential for catalysis (Probable). Also has reductase activity on hydrogen peroxide (H2O2) (PubMed:10849437) Induces actin and tubulin polymerization, leading to formation of cell membrane protrusions Enhances the transcriptional activity of estrogen receptors ESR1 and ESR2 Enhances the transcriptional activity of the estrogen receptor ESR2 only (PubMed:15199063). Mediates cell death induced by a combination of interferon-beta and retinoic acid (PubMed:9774665)","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q16881/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TXNRD1","classification":"Not Classified","n_dependent_lines":692,"n_total_lines":1208,"dependency_fraction":0.5728476821192053},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TXNRD1","total_profiled":1310},"omim":[{"mim_id":"616967","title":"THIOREDOXIN DOMAIN-CONTAINING PROTEIN 17; TXNDC17","url":"https://www.omim.org/entry/616967"},{"mim_id":"612986","title":"EP300-INTERACTING INHIBITOR OF DIFFERENTIATION 3; EID3","url":"https://www.omim.org/entry/612986"},{"mim_id":"609063","title":"THIOREDOXIN 2; TXN2","url":"https://www.omim.org/entry/609063"},{"mim_id":"606448","title":"THIOREDOXIN REDUCTASE 2; TXNRD2","url":"https://www.omim.org/entry/606448"},{"mim_id":"606254","title":"SELENOPROTEIN F; SELENOF","url":"https://www.omim.org/entry/606254"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TXNRD1"},"hgnc":{"alias_symbol":["TXNR","GRIM-12","Trxr1","TXNR1"],"prev_symbol":[]},"alphafold":{"accession":"Q16881","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16881","model_url":"","pae_url":"","plddt_mean":null},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TXNRD1","jax_strain_url":"https://www.jax.org/strain/search?query=TXNRD1"},"sequence":{"accession":"Q16881","fasta_url":"https://rest.uniprot.org/uniprotkb/Q16881.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q16881/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16881"}},"corpus_meta":[{"pmid":"26058897","id":"PMC_26058897","title":"TrxR1 as a potent regulator of the Nrf2-Keap1 response system.","date":"2015","source":"Antioxidants & redox signaling","url":"https://pubmed.ncbi.nlm.nih.gov/26058897","citation_count":201,"is_preprint":false},{"pmid":"37087975","id":"PMC_37087975","title":"The ferroptosis inducing compounds RSL3 and ML162 are not direct inhibitors of GPX4 but of TXNRD1.","date":"2023","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/37087975","citation_count":171,"is_preprint":false},{"pmid":"24763048","id":"PMC_24763048","title":"Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo.","date":"2014","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/24763048","citation_count":150,"is_preprint":false},{"pmid":"26963494","id":"PMC_26963494","title":"Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer.","date":"2016","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/26963494","citation_count":109,"is_preprint":false},{"pmid":"31367013","id":"PMC_31367013","title":"SLC27A5 deficiency activates NRF2/TXNRD1 pathway by increased lipid peroxidation in HCC.","date":"2019","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/31367013","citation_count":98,"is_preprint":false},{"pmid":"16510263","id":"PMC_16510263","title":"Sublethal concentrations of diverse gold compounds inhibit mammalian cytosolic thioredoxin reductase (TrxR1).","date":"2006","source":"Toxicology in vitro : an international journal published in association with BIBRA","url":"https://pubmed.ncbi.nlm.nih.gov/16510263","citation_count":95,"is_preprint":false},{"pmid":"31601260","id":"PMC_31601260","title":"Dietary intakes and biomarker patterns of folate, vitamin B6, and vitamin B12 can be associated with cognitive impairment by hypermethylation of redox-related genes NUDT15 and TXNRD1.","date":"2019","source":"Clinical epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/31601260","citation_count":84,"is_preprint":false},{"pmid":"30590310","id":"PMC_30590310","title":"Curcuminoid B63 induces ROS-mediated paraptosis-like cell death by targeting TrxR1 in gastric cells.","date":"2018","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/30590310","citation_count":82,"is_preprint":false},{"pmid":"37148740","id":"PMC_37148740","title":"NFATc1-mediated expression of SLC7A11 drives sensitivity to TXNRD1 inhibitors in osteoclast precursors.","date":"2023","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/37148740","citation_count":79,"is_preprint":false},{"pmid":"31384178","id":"PMC_31384178","title":"miR-125b-5p inhibits cell proliferation, migration, and invasion in hepatocellular carcinoma via targeting TXNRD1.","date":"2019","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/31384178","citation_count":77,"is_preprint":false},{"pmid":"31097586","id":"PMC_31097586","title":"TrxR1, Gsr, and oxidative stress determine hepatocellular carcinoma malignancy.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31097586","citation_count":70,"is_preprint":false},{"pmid":"21199936","id":"PMC_21199936","title":"Selenoprotein TRXR-1 and GSR-1 are essential for removal of old cuticle during molting in Caenorhabditis elegans.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21199936","citation_count":63,"is_preprint":false},{"pmid":"22198266","id":"PMC_22198266","title":"Hepatocyte DNA replication in growing liver requires either glutathione or a single allele of txnrd1.","date":"2011","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22198266","citation_count":58,"is_preprint":false},{"pmid":"19838062","id":"PMC_19838062","title":"p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA.","date":"2009","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/19838062","citation_count":58,"is_preprint":false},{"pmid":"23743293","id":"PMC_23743293","title":"A Txnrd1-dependent metabolic switch alters hepatic lipogenesis, glycogen storage, and detoxification.","date":"2013","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23743293","citation_count":57,"is_preprint":false},{"pmid":"23824739","id":"PMC_23824739","title":"KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer.","date":"2013","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/23824739","citation_count":57,"is_preprint":false},{"pmid":"32219156","id":"PMC_32219156","title":"Irreversible TrxR1 inhibitors block STAT3 activity and induce cancer cell death.","date":"2020","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/32219156","citation_count":55,"is_preprint":false},{"pmid":"29371830","id":"PMC_29371830","title":"A possible role for selenoprotein glutathione peroxidase (GPx1) and thioredoxin reductases (TrxR1) in thyroid cancer: our experience in thyroid surgery.","date":"2018","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/29371830","citation_count":53,"is_preprint":false},{"pmid":"34917232","id":"PMC_34917232","title":"TXNRD1: A Key Regulator Involved in the Ferroptosis of CML Cells Induced by Cysteine Depletion In Vitro.","date":"2021","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/34917232","citation_count":51,"is_preprint":false},{"pmid":"26919094","id":"PMC_26919094","title":"Selective killing of gastric cancer cells by a small molecule via targeting TrxR1 and ROS-mediated ER stress activation.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26919094","citation_count":47,"is_preprint":false},{"pmid":"33491733","id":"PMC_33491733","title":"Berberine accelerated wound healing by restoring TrxR1/JNK in diabetes.","date":"2021","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/33491733","citation_count":46,"is_preprint":false},{"pmid":"26743692","id":"PMC_26743692","title":"TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition.","date":"2016","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/26743692","citation_count":45,"is_preprint":false},{"pmid":"30619751","id":"PMC_30619751","title":"PCK1 Downregulation Promotes TXNRD1 Expression and Hepatoma Cell Growth via the Nrf2/Keap1 Pathway.","date":"2018","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30619751","citation_count":45,"is_preprint":false},{"pmid":"28775321","id":"PMC_28775321","title":"MiR-23-TrxR1 as a novel molecular axis in skeletal muscle differentiation.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28775321","citation_count":44,"is_preprint":false},{"pmid":"33345387","id":"PMC_33345387","title":"DIAPH3 promotes pancreatic cancer progression by activating selenoprotein TrxR1-mediated antioxidant effects.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33345387","citation_count":43,"is_preprint":false},{"pmid":"31680962","id":"PMC_31680962","title":"Piperlongumine, a Novel TrxR1 Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cells by ROS-Mediated ER Stress.","date":"2019","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31680962","citation_count":43,"is_preprint":false},{"pmid":"25078326","id":"PMC_25078326","title":"The Au clusters induce tumor cell apoptosis via specifically targeting thioredoxin reductase 1 (TrxR1) and suppressing its activity.","date":"2014","source":"Chemical communications (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25078326","citation_count":43,"is_preprint":false},{"pmid":"31920141","id":"PMC_31920141","title":"LncRNA FTX inhibition restrains osteosarcoma proliferation and migration via modulating miR-320a/TXNRD1.","date":"2020","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31920141","citation_count":41,"is_preprint":false},{"pmid":"33575477","id":"PMC_33575477","title":"microRNA-130b-3p Contained in MSC-Derived EVs Promotes Lung Cancer Progression by Regulating the FOXO3/NFE2L2/TXNRD1 Axis.","date":"2020","source":"Molecular therapy oncolytics","url":"https://pubmed.ncbi.nlm.nih.gov/33575477","citation_count":38,"is_preprint":false},{"pmid":"31113439","id":"PMC_31113439","title":"Curcuminoid WZ35 synergize with cisplatin by inducing ROS production and inhibiting TrxR1 activity in gastric cancer cells.","date":"2019","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/31113439","citation_count":36,"is_preprint":false},{"pmid":"31176737","id":"PMC_31176737","title":"Curcuminoid WZ26, a TrxR1 inhibitor, effectively inhibits colon cancer cell growth and enhances cisplatin-induced cell death through the induction of ROS.","date":"2019","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31176737","citation_count":35,"is_preprint":false},{"pmid":"30609207","id":"PMC_30609207","title":"Alantolactone promotes ER stress-mediated apoptosis by inhibition of TrxR1 in triple-negative breast cancer cell lines and in a mouse model.","date":"2019","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30609207","citation_count":34,"is_preprint":false},{"pmid":"28232204","id":"PMC_28232204","title":"Homozygous mutation in TXNRD1 is associated with genetic generalized epilepsy.","date":"2017","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28232204","citation_count":33,"is_preprint":false},{"pmid":"22836943","id":"PMC_22836943","title":"Two thioredoxin reductases, trxr-1 and trxr-2, have differential physiological roles in Caenorhabditis elegans.","date":"2012","source":"Molecules and cells","url":"https://pubmed.ncbi.nlm.nih.gov/22836943","citation_count":29,"is_preprint":false},{"pmid":"35936029","id":"PMC_35936029","title":"Selective cellular probes for mammalian thioredoxin reductase TrxR1: rational design of RX1, a modular 1,2-thiaselenane redox probe.","date":"2022","source":"Chem","url":"https://pubmed.ncbi.nlm.nih.gov/35936029","citation_count":29,"is_preprint":false},{"pmid":"28454363","id":"PMC_28454363","title":"MicroRNA-124 regulates the radiosensitivity of non-small cell lung cancer cells by targeting TXNRD1.","date":"2017","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/28454363","citation_count":29,"is_preprint":false},{"pmid":"24254253","id":"PMC_24254253","title":"Selenite protects Caenorhabditis elegans from oxidative stress via DAF-16 and TRXR-1.","date":"2013","source":"Molecular nutrition & food research","url":"https://pubmed.ncbi.nlm.nih.gov/24254253","citation_count":28,"is_preprint":false},{"pmid":"28743999","id":"PMC_28743999","title":"Selenocysteine induces apoptosis in human glioma cells: evidence for TrxR1-targeted inhibition and signaling crosstalk.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28743999","citation_count":27,"is_preprint":false},{"pmid":"24853413","id":"PMC_24853413","title":"Sec-containing TrxR1 is essential for self-sufficiency of cells by control of glucose-derived H2O2.","date":"2014","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/24853413","citation_count":27,"is_preprint":false},{"pmid":"36319631","id":"PMC_36319631","title":"USF2-mediated upregulation of TXNRD1 contributes to hepatocellular carcinoma progression by activating Akt/mTOR signaling.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36319631","citation_count":25,"is_preprint":false},{"pmid":"30668191","id":"PMC_30668191","title":"Potent inhibition of gastric cancer cells by a natural compound via inhibiting TrxR1 activity and activating ROS-mediated p38 MAPK pathway.","date":"2019","source":"Free radical research","url":"https://pubmed.ncbi.nlm.nih.gov/30668191","citation_count":25,"is_preprint":false},{"pmid":"33292234","id":"PMC_33292234","title":"Circ0120816 acts as an oncogene of esophageal squamous cell carcinoma by inhibiting miR-1305 and releasing TXNRD1.","date":"2020","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/33292234","citation_count":24,"is_preprint":false},{"pmid":"37676391","id":"PMC_37676391","title":"Deferoxamine Mitigates Ferroptosis and Inflammation in Hippocampal Neurons After Subarachnoid Hemorrhage by Activating the Nrf2/TXNRD1 Axis.","date":"2023","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/37676391","citation_count":24,"is_preprint":false},{"pmid":"26331426","id":"PMC_26331426","title":"Hirsutinolide Series Inhibit Stat3 Activity, Alter GCN1, MAP1B, Hsp105, G6PD, Vimentin, TrxR1, and Importin α-2 Expression, and Induce Antitumor Effects against Human Glioma.","date":"2015","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26331426","citation_count":24,"is_preprint":false},{"pmid":"28338004","id":"PMC_28338004","title":"TIGAR knockdown radiosensitizes TrxR1-overexpressing glioma in vitro and in vivo via inhibiting Trx1 nuclear transport.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28338004","citation_count":23,"is_preprint":false},{"pmid":"32596335","id":"PMC_32596335","title":"Licochalcone a Induces ROS-Mediated Apoptosis through TrxR1 Inactivation in Colorectal Cancer Cells.","date":"2020","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/32596335","citation_count":23,"is_preprint":false},{"pmid":"25753394","id":"PMC_25753394","title":"Trx1/TrxR1 system regulates post-selected DP thymocytes survival by modulating ASK1-JNK/p38 MAPK activities.","date":"2015","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/25753394","citation_count":23,"is_preprint":false},{"pmid":"38267705","id":"PMC_38267705","title":"TXNRD1 drives the innate immune response in senescent cells with implications for age-associated inflammation.","date":"2024","source":"Nature aging","url":"https://pubmed.ncbi.nlm.nih.gov/38267705","citation_count":22,"is_preprint":false},{"pmid":"32021440","id":"PMC_32021440","title":"Allylated Curcumin Analog CA6 Inhibits TrxR1 and Leads to ROS-Dependent Apoptotic Cell Death in Gastric Cancer Through Akt-FoxO3a.","date":"2020","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/32021440","citation_count":22,"is_preprint":false},{"pmid":"31400708","id":"PMC_31400708","title":"Novel electrophilic amides amenable by the Ugi reaction perturb thioredoxin system via thioredoxin reductase 1 (TrxR1) inhibition: Identification of DVD-445 as a new lead compound for anticancer therapy.","date":"2019","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31400708","citation_count":22,"is_preprint":false},{"pmid":"35569514","id":"PMC_35569514","title":"Diffractaic acid, a novel TrxR1 inhibitor, induces cytotoxicity, apoptosis, and antimigration in human breast cancer cells.","date":"2022","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/35569514","citation_count":21,"is_preprint":false},{"pmid":"19654027","id":"PMC_19654027","title":"The human thioredoxin reductase-1 splice variant TXNRD1_v3 is an atypical inducer of cytoplasmic filaments and cell membrane filopodia.","date":"2009","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/19654027","citation_count":21,"is_preprint":false},{"pmid":"22820176","id":"PMC_22820176","title":"TrxR1 and GPx2 are potently induced by isothiocyanates and selenium, and mutually cooperate to protect Caco-2 cells against free radical-mediated cell death.","date":"2012","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/22820176","citation_count":21,"is_preprint":false},{"pmid":"33134322","id":"PMC_33134322","title":"Novel TrxR1 Inhibitors Show Potential for Glioma Treatment by Suppressing the Invasion and Sensitizing Glioma Cells to Chemotherapy.","date":"2020","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/33134322","citation_count":20,"is_preprint":false},{"pmid":"29670693","id":"PMC_29670693","title":"Manumycin A Is a Potent Inhibitor of Mammalian Thioredoxin Reductase-1 (TrxR-1).","date":"2018","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/29670693","citation_count":20,"is_preprint":false},{"pmid":"23413027","id":"PMC_23413027","title":"The rare TXNRD1_v3 (\"v3\") splice variant of human thioredoxin reductase 1 protein is targeted to membrane rafts by N-acylation and induces filopodia independently of its redox active site integrity.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23413027","citation_count":18,"is_preprint":false},{"pmid":"36893814","id":"PMC_36893814","title":"Nitrovin (difurazone), an antibacterial growth promoter, induces ROS-mediated paraptosis-like cell death by targeting thioredoxin reductase 1 (TrxR1).","date":"2023","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36893814","citation_count":17,"is_preprint":false},{"pmid":"30677045","id":"PMC_30677045","title":"Up-regulation of antioxidative proteins TRX1, TXNL1 and TXNRD1 in the cortex of PTZ kindling seizure model mice.","date":"2019","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30677045","citation_count":17,"is_preprint":false},{"pmid":"17937623","id":"PMC_17937623","title":"Effect of selenium on thioredoxin reductase activity in Txnrd1 or Txnrd2 hemizygous mice.","date":"2007","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17937623","citation_count":17,"is_preprint":false},{"pmid":"29416738","id":"PMC_29416738","title":"PARP-1 inhibitors sensitize HNSCC cells to APR-246 by inactivation of thioredoxin reductase 1 (TrxR1) and promotion of ROS accumulation.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29416738","citation_count":17,"is_preprint":false},{"pmid":"36008942","id":"PMC_36008942","title":"Selenocysteine Machinery Primarily Supports TXNRD1 and GPX4 Functions and Together They Are Functionally Linked with SCD and PRDX6.","date":"2022","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/36008942","citation_count":17,"is_preprint":false},{"pmid":"38537439","id":"PMC_38537439","title":"Withaferin A, a natural thioredoxin reductase 1 (TrxR1) inhibitor, synergistically enhances the antitumor efficacy of sorafenib through ROS-mediated ER stress and DNA damage in hepatocellular carcinoma cells.","date":"2023","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38537439","citation_count":16,"is_preprint":false},{"pmid":"36370550","id":"PMC_36370550","title":"Discovery of novel hydroxyamidine based indoleamine 2,3-dioxygenase 1 (IDO1) and thioredoxin reductase 1 (TrxR1) dual inhibitors.","date":"2022","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36370550","citation_count":16,"is_preprint":false},{"pmid":"26064428","id":"PMC_26064428","title":"Antioxidants and Quality of Aging: Further Evidences for a Major Role of TXNRD1 Gene Variability on Physical Performance at Old Age.","date":"2015","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/26064428","citation_count":16,"is_preprint":false},{"pmid":"34537465","id":"PMC_34537465","title":"N-γ-(L-glutamyl)-L-selenomethionine shows neuroprotective effects against Parkinson's disease associated with SKN-1/Nrf2 and TRXR-1 in Caenorhabditis elegans.","date":"2021","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34537465","citation_count":16,"is_preprint":false},{"pmid":"33649852","id":"PMC_33649852","title":"miR‑875‑5p regulates IR and inflammation via targeting TXNRD1 in gestational diabetes rats.","date":"2021","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/33649852","citation_count":15,"is_preprint":false},{"pmid":"37064873","id":"PMC_37064873","title":"Selenium-ruthenium complex blocks H1N1 influenza virus-induced cell damage by activating GPx1/TrxR1.","date":"2023","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/37064873","citation_count":14,"is_preprint":false},{"pmid":"36012584","id":"PMC_36012584","title":"Expression of TXNRD1, HSPA4L and ATP1B1 Genes Associated with the Freezability of Boar Sperm.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36012584","citation_count":13,"is_preprint":false},{"pmid":"36335879","id":"PMC_36335879","title":"miR-3614-5p downregulation promotes cadmium-induced breast cancer cell proliferation and metastasis by targeting TXNRD1.","date":"2022","source":"Ecotoxicology and environmental safety","url":"https://pubmed.ncbi.nlm.nih.gov/36335879","citation_count":13,"is_preprint":false},{"pmid":"30225271","id":"PMC_30225271","title":"miR-125a Suppresses TrxR1 Expression and Is Involved in H2O2-Induced Oxidative Stress in Endothelial Cells.","date":"2018","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/30225271","citation_count":13,"is_preprint":false},{"pmid":"33640630","id":"PMC_33640630","title":"Design, synthesis and biological evaluations of diverse Michael acceptor-based phenazine hybrid molecules as TrxR1 inhibitors.","date":"2021","source":"Bioorganic chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33640630","citation_count":11,"is_preprint":false},{"pmid":"38086796","id":"PMC_38086796","title":"Elovanoid-N34 modulates TXNRD1 key in protection against oxidative stress-related diseases.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/38086796","citation_count":10,"is_preprint":false},{"pmid":"25379386","id":"PMC_25379386","title":"Prenatal expression of thioredoxin reductase 1 (TRXR1) and microsomal glutathione transferase 1 (MGST1) in humans.","date":"2014","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/25379386","citation_count":10,"is_preprint":false},{"pmid":"36602827","id":"PMC_36602827","title":"A Novel TrxR1 Inhibitor Regulates NK and CD8+ T Cell Infiltration and Cytotoxicity, Enhancing the Efficacy of Anti-PD-1 Immunotherapy against Hepatocarcinoma.","date":"2023","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/36602827","citation_count":10,"is_preprint":false},{"pmid":"36308906","id":"PMC_36308906","title":"Targeted inhibition of TXNRD1 prevents cartilage extracellular matrix degeneration by activating Nrf2 pathway in osteoarthritis.","date":"2022","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/36308906","citation_count":8,"is_preprint":false},{"pmid":"23154180","id":"PMC_23154180","title":"Simvastatin inhibits the core promoter of the TXNRD1 gene and lowers cellular TrxR activity in HepG2 cells.","date":"2012","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/23154180","citation_count":8,"is_preprint":false},{"pmid":"36578523","id":"PMC_36578523","title":"Metabolism-Related Gene TXNRD1 Regulates Inflammation and Oxidative Stress Induced by Cigarette Smoke through the Nrf2/HO-1 Pathway in the Small Airway Epithelium.","date":"2022","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/36578523","citation_count":8,"is_preprint":false},{"pmid":"38164168","id":"PMC_38164168","title":"Combination of TrxR1 inhibitor and lenvatinib triggers ROS-dependent cell death in human lung cancer cells.","date":"2024","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38164168","citation_count":7,"is_preprint":false},{"pmid":"39869029","id":"PMC_39869029","title":"Design of ROS-Triggered Sesquiterpene Lactone SC Prodrugs as TrxR1 Covalent Inhibitors for the Treatment of Non-Small Cell Lung Cancer.","date":"2025","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39869029","citation_count":7,"is_preprint":false},{"pmid":"22548205","id":"PMC_22548205","title":"Genetic Variations in TXNRD1 as Potential Predictors of Drug-Induced Liver Injury.","date":"2011","source":"Allergy, asthma & immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/22548205","citation_count":7,"is_preprint":false},{"pmid":"38565059","id":"PMC_38565059","title":"Synergistic targeting of TrxR1 and ATM/AKT pathway in human colon cancer cells.","date":"2024","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/38565059","citation_count":6,"is_preprint":false},{"pmid":"36754152","id":"PMC_36754152","title":"TXNRD1 knockdown inhibits the proliferation of endothelial cells subjected to oscillatory shear stress via activation of the endothelial nitric oxide synthase/apoptosis pathway.","date":"2023","source":"Biochimica et biophysica acta. Molecular cell research","url":"https://pubmed.ncbi.nlm.nih.gov/36754152","citation_count":6,"is_preprint":false},{"pmid":"40059270","id":"PMC_40059270","title":"Isowalsuranolide targets TrxR1/2 and triggers lysosomal biogenesis and autophagy via the p53-TFEB/TFE3 axis.","date":"2025","source":"Science China. Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40059270","citation_count":5,"is_preprint":false},{"pmid":"35527491","id":"PMC_35527491","title":"[Construction and identification of a HEK293 cell line with stable TrxR1 overexpression].","date":"2022","source":"Nan fang yi ke da xue xue bao = Journal of Southern Medical University","url":"https://pubmed.ncbi.nlm.nih.gov/35527491","citation_count":5,"is_preprint":false},{"pmid":"40143066","id":"PMC_40143066","title":"Micheliolide Alleviates Hepatic Fibrosis by Inhibiting Autophagy in Hepatic Stellate Cells via the TrxR1/2-Mediated ROS/MEK/ERK Pathway.","date":"2025","source":"Pharmaceuticals (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/40143066","citation_count":5,"is_preprint":false},{"pmid":"39983285","id":"PMC_39983285","title":"Cellular activity of the cytosolic selenoprotein thioredoxin reductase 1 (TXNRD1) is modulated by copper and zinc levels in the cell culture medium.","date":"2025","source":"Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS)","url":"https://pubmed.ncbi.nlm.nih.gov/39983285","citation_count":5,"is_preprint":false},{"pmid":"38153696","id":"PMC_38153696","title":"LncRNA CARD8-AS1 suppresses lung adenocarcinoma progression by enhancing TRIM25-mediated ubiquitination of TXNRD1.","date":"2024","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/38153696","citation_count":5,"is_preprint":false},{"pmid":"39668144","id":"PMC_39668144","title":"Deciphering the Comprehensive Structure-Activity Relationship of Sunshinamide for Breast Cancer Therapy through Dual Modulation of Apoptotic and Ferroptotic Pathways via TrxR1 and Gpx4 Inhibition.","date":"2024","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39668144","citation_count":5,"is_preprint":false},{"pmid":"39141196","id":"PMC_39141196","title":"Pharmacological Inhibition of TXNRD1 by a Small Molecule Flavonoid Butein Overcomes Cisplatin Resistance in Lung Cancer Cells.","date":"2024","source":"Biological trace element research","url":"https://pubmed.ncbi.nlm.nih.gov/39141196","citation_count":5,"is_preprint":false},{"pmid":"34999996","id":"PMC_34999996","title":"Correlation between TXNRD1/HO-1 expression and response to neoadjuvant chemoradiation therapy in patients with esophageal squamous cell carcinoma.","date":"2022","source":"Esophagus : official journal of the Japan Esophageal Society","url":"https://pubmed.ncbi.nlm.nih.gov/34999996","citation_count":5,"is_preprint":false},{"pmid":"38733769","id":"PMC_38733769","title":"Inducing ubiquitination and degradation of TrxR1 protein by LW-216 promotes apoptosis in non-small cell lung cancer via triggering ROS production.","date":"2024","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/38733769","citation_count":5,"is_preprint":false},{"pmid":"39243480","id":"PMC_39243480","title":"Endogenous electrophiles and peroxymonocarbonate can link tyrosine phosphorylation cascades with the cytosolic TXNRD1 selenoprotein and the KEAP1/NRF2 system.","date":"2024","source":"Current opinion in chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/39243480","citation_count":4,"is_preprint":false},{"pmid":"38053374","id":"PMC_38053374","title":"RASSF1A promotes radiosensitivity in nasopharyngeal carcinoma by promoting FoxO3a and inhibiting the Nrf2/TXNRD1 signaling pathway.","date":"2023","source":"Neoplasma","url":"https://pubmed.ncbi.nlm.nih.gov/38053374","citation_count":4,"is_preprint":false},{"pmid":"36780763","id":"PMC_36780763","title":"Thimerosal, a competitive thioredoxin reductase 1 (TrxR1) inhibitor discovered via high-throughput screening.","date":"2023","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/36780763","citation_count":4,"is_preprint":false},{"pmid":"27706680","id":"PMC_27706680","title":"Association between TXNRD1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a prospective study.","date":"2016","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/27706680","citation_count":4,"is_preprint":false},{"pmid":"38682343","id":"PMC_38682343","title":"Investigation of the effects of thiazole compounds on thioredoxin reductase 1 (TrxR1), glutathione S-transferase (GST), and glutathione reductase (GR) targeted human brain glioblastoma cancer (U-87 MG).","date":"2024","source":"Biotechnology and applied biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38682343","citation_count":4,"is_preprint":false},{"pmid":"34412665","id":"PMC_34412665","title":"Ethaselen synergizes with oxaliplatin in tumor growth inhibition by inducing ROS production and inhibiting TrxR1 activity in gastric cancer.","date":"2021","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/34412665","citation_count":4,"is_preprint":false},{"pmid":"41016297","id":"PMC_41016297","title":"Glaucocalyxin A induces autophagy-mediated ferroptosis by targeting PRDX1 and TXNRD1 proteins in non-small cell lung cancer.","date":"2025","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/41016297","citation_count":3,"is_preprint":false},{"pmid":"38243044","id":"PMC_38243044","title":"PSMD12 promotes non-small cell lung cancer progression through activating the Nrf2/TrxR1 pathway.","date":"2024","source":"Genes & genomics","url":"https://pubmed.ncbi.nlm.nih.gov/38243044","citation_count":3,"is_preprint":false},{"pmid":"35355475","id":"PMC_35355475","title":"[Construction of a stable TrxR1 knockout HCT-116 cell line using CRISPR/Cas9 gene editing system].","date":"2022","source":"Sheng wu gong cheng xue bao = Chinese journal of biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/35355475","citation_count":3,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53301,"output_tokens":7278,"usd":0.134537},"stage2":{"model":"claude-opus-4-6","input_tokens":10946,"output_tokens":4639,"usd":0.256057},"total_usd":0.390594,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2023,\n      \"finding\": \"RSL3 and ML162, commonly used as GPX4 inhibitors to study ferroptosis, are in fact potent inhibitors of TXNRD1 and lack capacity to inhibit recombinant selenoprotein GPX4 enzymatic activity; other known TXNRD1 inhibitors (auranofin, TRi-1, TRi-2) also induce cell death but through ferroptosis-independent mechanisms.\",\n      \"method\": \"In vitro enzymatic activity assays with recombinant GPX4 and TXNRD1, cell death assays with ferrostatin-1\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with recombinant proteins, multiple orthogonal assays\",\n      \"pmids\": [\"37087975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TXNRD1 drives the senescence-associated secretory phenotype (SASP) and inflammaging through the cGAS-STING innate immune pathway independently of its enzymatic activity; TXNRD1 localizes to cytoplasmic chromatin fragments, physically interacts with cGAS in a senescence-dependent manner, enhances cGAS enzymatic activity, and is required for SASP-mediated tumor-promoting and immune surveillance functions in vivo.\",\n      \"method\": \"Co-immunoprecipitation, subcellular fractionation, cGAS activity assays, mouse models with TXNRD1 inhibitors selective for enzymatic vs. cGAS-interaction functions, loss-of-function studies\",\n      \"journal\": \"Nature aging\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP, functional enzymatic assays, multiple in vivo models, orthogonal inhibitors distinguishing enzymatic vs. protein-interaction roles\",\n      \"pmids\": [\"38267705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Selenocysteine (Sec)-containing TrxR1 is absolutely required for self-sufficient growth of mouse embryonic fibroblasts under high-glucose conditions due to its essential role in eliminating glucose-derived H2O2; Sec-devoid TrxR1 variants cannot rescue this function.\",\n      \"method\": \"Txnrd1 knockout MEFs reconstituted with wild-type vs. Sec-devoid TrxR1 variants, H2O2 measurement, cell death assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — genetic reconstitution with mutagenesis in defined cell system\",\n      \"pmids\": [\"24853413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"In vivo hepatocyte DNA replication requires either glutathione (GSH) or at least one functional allele of Txnrd1; complete loss of both pathways (Txnrd1-null hepatocytes + BSO-mediated GSH depletion) severely impairs hepatocyte replication, establishing that TrxR1 and GSH independently support ribonucleotide reductase electron donation in vivo.\",\n      \"method\": \"Genetic mouse models (Txnrd1 conditional knockout), BSO treatment, replicative index measurement, TrxR activity assays\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in vivo with defined mechanistic readout, controlled genetic backgrounds\",\n      \"pmids\": [\"22198266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Hepatocyte-specific disruption of Txnrd1 causes a metabolic switch repressing lipogenic genes, engorging periportal hepatocytes with glycogen, upregulating glutathione biosynthesis, UDP-glucuronate machinery, glutathione-S-transferases, UDP-glucuronyl-transferases, and xenobiotic exporters; NAPQI (from acetaminophen) directly inactivates TrxR1, yet Txnrd1-null livers are resistant to APAP hepatotoxicity due to constitutively enhanced GSH and glucuronidation systems.\",\n      \"method\": \"Hepatocyte-specific Txnrd1 conditional knockout mice, metabolomic profiling, APAP hepatotoxicity challenge, in vitro NAPQI-TrxR1 inactivation assay\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — genetic KO with metabolomics, in vitro enzymatic inactivation, in vivo toxicology challenge\",\n      \"pmids\": [\"23743293\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"RITA binds TrxR1 non-covalently and inhibits its activity in vitro and in cancer cells in a p53-dependent manner; RITA also induces a ~130 kDa stable covalently linked TrxR1 dimer and increases ROS specifically in cancer cells but not normal fibroblasts, in a p53-dependent fashion.\",\n      \"method\": \"In vitro TrxR1 activity assay, cell-based TrxR activity measurement, ROS detection, Western blot for TrxR1 dimer\",\n      \"journal\": \"Cell cycle\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro + cellular assays, p53-dependence shown, but mechanistic detail on non-covalent binding is limited\",\n      \"pmids\": [\"19838062\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TrxR1 inhibition (via auranofin or siRNA) combined with AKT inhibition (MK2206) induces synthetic lethality in NSCLC cells through KEAP1/NRF2-dependent ROS accumulation and JNK activation; wild-type KEAP1 function is required for this synthetic lethality.\",\n      \"method\": \"Genome-wide siRNA library screen, combinatorial drug treatment, KEAP1 mutant cell lines, ROS measurement, in vivo xenograft\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic screen plus mechanistic follow-up with genetic controls, replicated in vivo\",\n      \"pmids\": [\"23824739\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TrxR1 inhibition by irreversible inhibitors induces oxidation of Prx2 and STAT3, which blocks STAT3-dependent transcription; previously identified STAT3 inhibitors also inhibit TrxR1, and TrxR1 inhibitors block STAT3-dependent transcriptional activity through redox-mediated STAT3 oxidation.\",\n      \"method\": \"Luciferase reporter assays, TrxR1 inhibitor profiling, oxidation state analysis of Prx2 and STAT3, target engagement studies\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic link between TrxR1 inhibition and STAT3 oxidation established with multiple orthogonal approaches\",\n      \"pmids\": [\"32219156\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"In C. elegans, TRXR-1 (selenoprotein thioredoxin reductase) functions together with GSR-1 glutathione reductase to reduce disulfide bonds in the cuticle during molting; selenocysteine-to-cysteine TRXR-1 mutants fail to rescue molting defects, demonstrating strict selenocysteine dependence; exogenous reduced glutathione can substitute to induce apolysis.\",\n      \"method\": \"C. elegans genetic knockouts/mutants, selenocysteine-to-cysteine mutant rescue experiments, SELB-1 mutants (selenocysteine incorporation factor), exogenous GSH treatment, cuticle oxidation state analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — genetic reconstitution with selenocysteine mutagenesis in C. elegans ortholog, multiple genetic and biochemical approaches\",\n      \"pmids\": [\"21199936\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The TXNRD1_v3 splice variant (carrying an N-terminal glutaredoxin domain) forms dynamic cytoplasmic filaments and induces filopodia formation when overexpressed; both filament formation and filopodia are dependent on the glutaredoxin domain; filopodia but not filaments require actin polymerization.\",\n      \"method\": \"Live cell imaging, truncation mutants, actin polymerization inhibitors, overexpression in cell lines\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct live imaging with domain-mapping mutants, clean cellular phenotype\",\n      \"pmids\": [\"19654027\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TXNRD1_v3 membrane targeting is mediated by myristoylation and palmitoylation of its N-terminal MGC motif, directing it specifically to membrane rafts; v3-mediated filopodia induction is independent of redox-active Cys residues but dependent on membrane raft targeting.\",\n      \"method\": \"Site-directed mutagenesis of MGC motif, lipid fractionation, cholera toxin B co-localization, truncated mutant analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis of lipidation sites combined with fractionation and functional filopodia readout\",\n      \"pmids\": [\"23413027\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Diverse gold compounds (auranofin, gold sodium thiomalate, sodium aurothiosulfate, triphenyl phosphine gold chloride, gold acetate) all inhibit TrxR1 at nanomolar concentrations; Au(I)-phosphine compounds are most potent; ligand configuration rather than gold oxidation state determines inhibitory potency.\",\n      \"method\": \"Ex vivo TrxR1 activity assay with purified rat TrxR1, IC50 determination, comparison with cellular mitochondrial toxicity\",\n      \"journal\": \"Toxicology in vitro\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic assay with structure-activity analysis, single study\",\n      \"pmids\": [\"16510263\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Manumycin A irreversibly inhibits TrxR1 (IC50 272 nM with preincubation) by forming a Michael adduct with the selenocysteine residue in the C-terminal redox center, converting TrxR1 into a SecTRAP that uses NADPH to reduce oxygen to superoxide.\",\n      \"method\": \"In vitro TrxR1 activity assay with/without preincubation, time-dependence analysis, covalent modification evidence, superoxide production assay\",\n      \"journal\": \"ACS medicinal chemistry letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with mechanistic characterization of covalent selenocysteine modification\",\n      \"pmids\": [\"29670693\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"miR-23a and miR-23b directly bind the 3' UTR of TrxR1 mRNA, repressing its expression during early C2C12 myoblast differentiation; TrxR1 depletion promotes myogenic gene expression (myogenin, Myf5 upregulation; Cyclin D1 decrease), while TrxR1 overexpression delays myogenesis.\",\n      \"method\": \"3' UTR luciferase reporter assay, miRNA mimic/inhibitor transfection, TrxR1 KD and OE in C2C12 cells, myogenic marker expression analysis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct 3' UTR binding confirmed by reporter assay, functional rescue experiments, defined cellular phenotype\",\n      \"pmids\": [\"28775321\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Trx1/TrxR1 system regulates survival of post-selected CD69+ double-positive thymocytes by suppressing ASK1, JNK, and p38 MAPK phosphorylation and limiting Bim upregulation; TrxR1 inhibition specifically reduces post-selected DP thymocytes both in vitro and in vivo.\",\n      \"method\": \"TrxR1 inhibitor treatment in vitro and in vivo, Western blot for ASK1/JNK/p38 phosphorylation, flow cytometry for thymocyte subsets, Bim expression analysis\",\n      \"journal\": \"Immunology and cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo pharmacological inhibition with defined signaling pathway readout\",\n      \"pmids\": [\"25753394\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TXNRD1 attenuates the interaction between Trx1 and PTEN, resulting in accelerated PTEN degradation and consequent Akt/mTOR pathway activation, promoting HCC cell mobility and metastasis; USF2 is a transcriptional suppressor that directly binds two E-box sites in the TXNRD1 promoter to repress its expression.\",\n      \"method\": \"Co-IP (Trx1-PTEN interaction), siRNA knockdown, overexpression studies, ChIP/dual-luciferase for USF2-TXNRD1 promoter interaction, in vitro and in vivo xenograft models\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP demonstrating Trx1-PTEN interaction modulated by TXNRD1, promoter-binding confirmed by luciferase, functional in vivo validation\",\n      \"pmids\": [\"36319631\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"A homozygous TXNRD1 mutation (p.Pro190Leu) reduces enzyme activity to 16–34% of controls in patient fibroblasts and skeletal muscle; in vitro kinetic analysis of recombinant mutant TXNRD1 shows 30–40% lower kcat/Se values; reduced enzyme abundance was confirmed by 75Se labeling; patient fibroblasts show reduced resistance to H2O2 challenge.\",\n      \"method\": \"75Se labeling, Western blot, in vitro kinetic analysis of recombinant mutant protein, enzymatic activity assays in patient-derived cells, exome sequencing\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinetic analysis of recombinant mutant protein combined with patient-derived tissue enzymatic studies and Se-labeling\",\n      \"pmids\": [\"28232204\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"During RANKL-induced osteoclastogenesis, NFATc1 transcriptionally upregulates SLC7A11 (cystine transporter); TXNRD1 inhibition reduces intracellular disulfide reduction rate, causing cystine accumulation and disulfidptosis selectively in osteoclast precursors; this cell death is blocked by SLC7A11 inhibitors but not by ferroptosis, apoptosis, necroptosis, or autophagy inhibitors.\",\n      \"method\": \"NFATc1 transcriptional reporter assays, pharmacological TXNRD1 inhibition, SLC7A11 inhibitors, selective inhibitors of multiple death pathways, OVX mouse model in vivo\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection with multiple selective inhibitors and in vivo model, NFATc1-SLC7A11 transcriptional link confirmed\",\n      \"pmids\": [\"37148740\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The RX1 probe selectively targets mammalian TrxR1 via a cyclic selenenylsulfide that exploits TrxR1's unique selenolthiol chemistry; probe selectivity validated by TrxR1 knockout, selenium starvation, knock-in, and chemical inhibitors; used for quantitative live-cell high-throughput screening of TrxR1 inhibitors.\",\n      \"method\": \"Genetic KO, selenium starvation, knock-in complementation, chemical inhibitors, live-cell fluorescence imaging, high-throughput screening\",\n      \"journal\": \"Chem\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal genetic and chemical validation methods for probe selectivity\",\n      \"pmids\": [\"35936029\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TrxR1 and Gsr together maintain antioxidant defense in mouse liver; TrxR1-null livers develop threefold fewer DEN-induced tumors compared to wild-type, suggesting TrxR1 promotes carcinogen-induced cancer initiation; elevated oxidative stress (TrxR1/Gsr double-null) correlates with increased malignancy independently of Nrf2 expression within tumors.\",\n      \"method\": \"Conditional knockout mouse models (TrxR1-null, Gsr-null, double-null), DEN carcinogenesis model, DNA damage measurement, metabolomics, tumor burden quantification\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic mouse models with defined carcinogenesis challenge and metabolomic profiling\",\n      \"pmids\": [\"31097586\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Nrf2 positively regulates TXNRD1 protein expression, shown by co-immunoprecipitation and Western blotting; deferoxamine activates nuclear translocation of Nrf2 in hippocampal neurons and thereby upregulates TXNRD1 to suppress ferroptosis and inflammation after subarachnoid hemorrhage.\",\n      \"method\": \"Co-immunoprecipitation, Western blotting, Nrf2 pathway inhibitor (ML385), in vivo SAH mouse model, in vitro FIN56 ferroptosis model\",\n      \"journal\": \"Molecular neurobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — Co-IP for Nrf2-TXNRD1 regulation, pathway inhibitor used to confirm, in vivo model\",\n      \"pmids\": [\"37676391\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"lncRNA CARD8-AS1 acts as a scaffold to facilitate the interaction between TXNRD1 and E3 ubiquitin ligase TRIM25, promoting TXNRD1 degradation through the ubiquitin-proteasome pathway; TXNRD1 overexpression reverses the tumor-suppressive effects of CARD8-AS1 in lung adenocarcinoma.\",\n      \"method\": \"RNA pull-down, Co-IP, ubiquitination assays, rescue experiments with TXNRD1 overexpression, in vitro and in vivo functional studies\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — Co-IP and ubiquitination assay for TRIM25-TXNRD1 interaction, functional rescue, single lab\",\n      \"pmids\": [\"38153696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Glaucocalyxin A (GLA) selectively forms covalent bonds with Cys173 of PRDX1 and Cys59, Cys64, Cys497, and Sec498 of TXNRD1 (with reactivity order Sec498 > Cys59 > Cys497 > Cys64), inhibiting their enzymatic activities, disrupting redox homeostasis, and triggering autophagy-mediated ferroptosis in NSCLC cells.\",\n      \"method\": \"Activity-based protein profiling (ABPP), covalent binding site identification by mass spectrometry, computational chemistry, in vitro enzymatic activity assays, in vivo xenograft\",\n      \"journal\": \"Phytomedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — ABPP target identification with site-specific covalent modification confirmed by MS and computational analysis\",\n      \"pmids\": [\"41016297\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Elovanoid-N34 directly modulates TXNRD1 activity by binding to TXNRD1 isoforms 2 or 3 (identified by limited proteolysis screening), inducing structural changes at the FAD interface domain; ELV-N34 decreases both membrane and cytosolic TXNRD1 activity, revealing distinct subcellular localizations of the enzyme.\",\n      \"method\": \"Limited proteolysis (LiP) mass spectrometry screening, TXNRD1 silencing to confirm isoform specificity, TXNRD1 activity assays in membrane and cytosolic fractions\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — LiP-MS for direct target identification, isoform-specific silencing, subcellular fractionation activity assays\",\n      \"pmids\": [\"38086796\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ROS-triggered prodrug 5u releases active compound 6a, which covalently binds to Cys475 and Sec498 sites on TXNRD1, inhibiting its activity, disrupting redox homeostasis, and causing apoptosis and ferroptosis in NSCLC cells.\",\n      \"method\": \"Covalent binding site identification, in vitro TrxR1 activity assay, cell death mechanism assays (apoptosis/ferroptosis markers), in vivo xenograft and organoid models\",\n      \"journal\": \"Journal of medicinal chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with site-specific covalent modification, functional cell death assays, single study\",\n      \"pmids\": [\"39869029\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Butein irreversibly inhibits recombinant TXNRD1 in a time-dependent manner by modifying catalytic Cys residues, identified by TrxR1 mutant variants and LC-MS; cellular ROS accumulation results and reversal of cisplatin resistance is achieved through TXNRD1 inhibition.\",\n      \"method\": \"In vitro enzymatic assay with recombinant TXNRD1, TXNRD1 Cys mutant variants, LC-MS covalent modification identification, cellular ROS assays, cisplatin-resistant cell line studies\",\n      \"journal\": \"Biological trace element research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with mutagenesis and MS-confirmed covalent modification of catalytic residues\",\n      \"pmids\": [\"39141196\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Thimerosal competitively and reversibly inhibits TrxR1 with an IC50 of 24.08 nM, identified via a high-throughput screening assay based on enzyme kinetics.\",\n      \"method\": \"Enzyme kinetics-based high-throughput screening, IC50 determination, competitive inhibition mode analysis, cellular ROS assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic kinetics with defined inhibition mode, single study\",\n      \"pmids\": [\"36780763\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TXNRD1 knockdown in oscillatory shear stress (Oss)-treated human aortic endothelial cells inhibits their proliferation, migration, and tube formation by activating the eNOS/apoptosis pathway; L-NAME (eNOS inhibitor) reverses these effects, placing eNOS downstream of TXNRD1 in this context.\",\n      \"method\": \"TXNRD1 siRNA knockdown, Oss shear stress bioreactor, L-NAME pharmacological inhibition, proliferation/migration/tube formation assays, flow cytometry for apoptosis\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KD with pharmacological epistasis defining eNOS as downstream effector, defined cellular phenotype\",\n      \"pmids\": [\"36754152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TrxR1/2 inhibition by isowalsuranolide (Hdy-7) leads to ROS accumulation that activates p53 and subsequent lysosomal biogenesis via TFEB/TFE3 nuclear translocation; knockdown of TrxR1/2 phenocopies this effect; pharmacological or genetic inhibition of autophagy prevents Hdy-7-induced cell death, indicating autophagic cell death downstream of TrxR1/2 inhibition.\",\n      \"method\": \"TrxR1/2 knockdown, ROS scavenger (NAC), p53 knockdown, SESN2 knockdown, TFEB/TFE3 nuclear translocation assays, autophagy inhibition, in vitro TrxR activity assays\",\n      \"journal\": \"Science China. Life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KD combined with multiple pathway-specific inhibitors and nuclear translocation assays, mechanistic pathway defined\",\n      \"pmids\": [\"40059270\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TXNRD1 is a cytosolic selenoprotein thioredoxin reductase whose uniquely reactive selenocysteine (Sec) at the C-terminal redox center is the primary target for diverse electrophilic and gold-based inhibitors; it maintains redox homeostasis by reducing thioredoxin (Trx1) and eliminating glucose-derived H2O2 in a strictly Sec-dependent manner, supports hepatocyte proliferation and a metabolic program in liver, drives the SASP/inflammaging through a non-enzymatic interaction with cGAS to enhance innate immune signaling, regulates Nrf2/KEAP1-dependent antioxidant transcription, modulates PTEN stability via Trx1, controls T-cell development via ASK1-JNK/p38 suppression, and its splice variant v3 localizes to membrane rafts via N-acylation to induce filopodia through its glutaredoxin domain independently of redox activity.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"TXNRD1 encodes cytosolic thioredoxin reductase 1 (TrxR1), a selenoprotein oxidoreductase that serves as a central node in cellular redox homeostasis by reducing thioredoxin (Trx1) and eliminating reactive oxygen species in a selenocysteine (Sec)-dependent manner [PMID:24853413, PMID:22198266]. Its C-terminal Sec residue is the primary target of diverse electrophilic and gold-based inhibitors that form covalent adducts, converting the enzyme into a pro-oxidant SecTRAP [PMID:29670693, PMID:16510263, PMID:39141196]; TrxR1 and glutathione reductase constitute parallel, partially redundant reductive pathways that together supply electrons to ribonucleotide reductase for DNA synthesis and maintain hepatic metabolic programming [PMID:22198266, PMID:23743293, PMID:31097586]. Beyond its enzymatic role, TXNRD1 physically interacts with cGAS on cytoplasmic chromatin fragments to enhance cGAS enzymatic activity and drive the senescence-associated secretory phenotype independently of its reductase activity [PMID:38267705], and the TXNRD1_v3 splice variant localizes to membrane rafts via N-terminal myristoylation/palmitoylation to induce filopodia through its glutaredoxin domain independently of redox catalysis [PMID:23413027, PMID:19654027]. A homozygous TXNRD1 missense mutation (p.Pro190Leu) that reduces enzymatic activity to 16–34% of normal causes a generalized selenoprotein deficiency disorder [PMID:28232204].\",\n  \"teleology\": [\n    {\n      \"year\": 2006,\n      \"claim\": \"The question of how gold-based therapeutics target TrxR1 was resolved by showing that diverse gold compounds inhibit TrxR1 at nanomolar concentrations, with Au(I)-phosphine ligand configuration—not oxidation state—determining potency, establishing TrxR1 as a pharmacologically druggable selenoenzyme.\",\n      \"evidence\": \"In vitro IC50 determination with purified rat TrxR1 and structurally diverse gold compounds\",\n      \"pmids\": [\"16510263\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Binding site on TrxR1 not mapped\", \"Selectivity over TrxR2 not assessed\", \"In vivo target engagement not demonstrated\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"The identification of the TXNRD1_v3 splice variant revealed that its N-terminal glutaredoxin domain drives filopodia formation and cytoplasmic filament assembly independently of canonical TrxR1 reductase function, establishing a non-canonical cytoskeletal role for a TrxR1 isoform.\",\n      \"evidence\": \"Live-cell imaging of overexpressed v3 with truncation and domain-deletion mutants, actin polymerization inhibitors in cell lines\",\n      \"pmids\": [\"19654027\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous expression levels and physiological relevance of v3 unclear\", \"Binding partners mediating filopodia unknown\", \"Redox independence based on domain deletion, not active-site mutagenesis\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Genetic epistasis in vivo demonstrated that TrxR1 and glutathione constitute two parallel electron-supply pathways for hepatocyte DNA replication—likely converging on ribonucleotide reductase—resolving how cells tolerate loss of either pathway alone.\",\n      \"evidence\": \"Txnrd1 conditional knockout mice with BSO-mediated GSH depletion, replicative index measurement in hepatocytes\",\n      \"pmids\": [\"22198266\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct measurement of ribonucleotide reductase activity in double-depleted hepatocytes not performed\", \"Contribution of other reductases not excluded\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"The strict requirement for selenocysteine in TrxR catalysis was established across species: Sec-to-Cys mutants of C. elegans TRXR-1 fail to rescue molting, and Sec-devoid TrxR1 cannot eliminate glucose-derived H₂O₂ in mouse embryonic fibroblasts, proving that Sec is not a dispensable catalytic residue.\",\n      \"evidence\": \"Sec-to-Cys mutant rescue in C. elegans molting and in Txnrd1-null MEFs under high glucose; H₂O₂ measurement\",\n      \"pmids\": [\"21199936\", \"24853413\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for why Sec is required (redox potential, pKa) not resolved in these studies\", \"Whether any biological context allows Sec-devoid activity remains open\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Hepatocyte-specific Txnrd1 loss triggered a compensatory metabolic switch—upregulating GSH biosynthesis, glucuronidation, and xenobiotic export while repressing lipogenesis—revealing TrxR1 as a metabolic rheostat whose absence paradoxically confers resistance to acetaminophen hepatotoxicity.\",\n      \"evidence\": \"Hepatocyte-specific Txnrd1 conditional knockout mice with metabolomic profiling and APAP challenge; NAPQI shown to directly inactivate TrxR1 in vitro\",\n      \"pmids\": [\"23743293\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcriptional mediators of the metabolic switch not fully identified\", \"Whether Nrf2 drives all compensatory changes unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Membrane raft targeting of TXNRD1_v3 was shown to require N-terminal myristoylation and palmitoylation of the MGC motif, and filopodia induction depended on raft localization but not on redox-active cysteines, separating the structural/signaling role of v3 from enzymatic catalysis.\",\n      \"evidence\": \"Site-directed mutagenesis of MGC lipidation motif, lipid raft fractionation, cholera toxin B co-localization, filopodia quantification\",\n      \"pmids\": [\"23413027\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling partners at membrane rafts unidentified\", \"In vivo relevance of v3-driven filopodia not tested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"A synthetic lethal interaction between TrxR1 inhibition and AKT inhibition was discovered in NSCLC, dependent on intact KEAP1 function, linking TrxR1 to the KEAP1/NRF2 antioxidant axis and JNK activation as a cell death mechanism.\",\n      \"evidence\": \"Genome-wide siRNA screen combined with MK2206, KEAP1-mutant cell lines, ROS quantification, xenograft validation\",\n      \"pmids\": [\"23824739\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether TrxR1 directly modifies KEAP1 or acts indirectly via ROS not distinguished\", \"Generalizability beyond NSCLC not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"TrxR1 was placed upstream of the ASK1-JNK/p38-Bim apoptotic cascade in thymocytes, explaining how the Trx1/TrxR1 system supports survival of post-selected double-positive thymocytes during T-cell development.\",\n      \"evidence\": \"TrxR1 pharmacological inhibition in vitro and in vivo with phospho-ASK1/JNK/p38 and Bim readouts, flow cytometry of thymocyte subsets\",\n      \"pmids\": [\"25753394\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Genetic TrxR1 deletion in thymocytes not performed\", \"Whether Trx1 oxidation state directly controls ASK1 binding not shown in this system\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"A human homozygous TXNRD1 mutation (p.Pro190Leu) was shown to reduce enzymatic activity to 16–34% of normal in patient tissues, with recombinant mutant protein showing reduced kcat, establishing TXNRD1 as a disease gene for a selenoprotein deficiency disorder.\",\n      \"evidence\": \"Patient-derived fibroblast and muscle enzymatic assays, ⁷⁵Se labeling, recombinant mutant kinetic analysis, exome sequencing\",\n      \"pmids\": [\"28232204\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full clinical spectrum not defined\", \"Whether residual activity is from the mutant or compensatory pathways not resolved\", \"Only one family reported\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"The mechanism by which electrophilic inhibitors convert TrxR1 into a pro-oxidant was elucidated: manumycin A forms a Michael adduct specifically at the C-terminal Sec residue, generating a SecTRAP that channels NADPH electrons to O₂ to produce superoxide.\",\n      \"evidence\": \"In vitro preincubation kinetics, time-dependent irreversible inhibition, covalent modification evidence, superoxide production assay with purified TrxR1\",\n      \"pmids\": [\"29670693\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crystal structure of the SecTRAP not resolved\", \"In vivo superoxide generation from SecTRAP not quantified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"TrxR1 was shown to promote carcinogen-induced hepatocellular cancer initiation in vivo, as TrxR1-null livers developed threefold fewer DEN-induced tumors, while combined TrxR1/Gsr loss increased tumor malignancy independently of Nrf2, revealing opposing roles of moderate vs. excessive oxidative stress in tumorigenesis.\",\n      \"evidence\": \"Conditional TrxR1-null, Gsr-null, and double-null mouse liver models with DEN carcinogenesis, DNA damage and metabolomic profiling\",\n      \"pmids\": [\"31097586\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which TrxR1 promotes initiation (DNA damage tolerance vs. proliferation support) not fully defined\", \"Cell-autonomous vs. microenvironmental effects not separated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"TrxR1 was identified as an upstream regulator of STAT3 redox state: its inhibition causes Prx2 and STAT3 oxidation, blocking STAT3-dependent transcription and explaining off-target mechanisms of several 'STAT3 inhibitors'.\",\n      \"evidence\": \"Luciferase reporter assays, TrxR1 inhibitor profiling, Prx2/STAT3 oxidation state analysis\",\n      \"pmids\": [\"32219156\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether TrxR1→Trx1→Prx2→STAT3 is the sole pathway not excluded\", \"Direct Trx1-STAT3 interaction not demonstrated\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"TXNRD1 was shown to modulate PTEN stability by competing with PTEN for Trx1 binding; high TXNRD1 expression accelerates PTEN degradation and activates Akt/mTOR signaling, and USF2 directly represses TXNRD1 transcription via E-box elements.\",\n      \"evidence\": \"Co-IP for Trx1-PTEN interaction ± TXNRD1, ChIP/dual-luciferase for USF2-TXNRD1 promoter binding, xenograft models\",\n      \"pmids\": [\"36319631\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of PTEN degradation (ubiquitin ligase identity) not identified\", \"Whether this occurs in non-HCC contexts unknown\", \"Reciprocal Co-IP for TXNRD1-Trx1 competition not fully shown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"The widely used 'GPX4 inhibitors' RSL3 and ML162 were demonstrated to potently inhibit TXNRD1 without inhibiting recombinant GPX4, fundamentally reframing the ferroptosis field's tool compound specificity and indicating that many attributed GPX4-dependent effects may reflect TXNRD1 inhibition.\",\n      \"evidence\": \"In vitro enzymatic assays with recombinant GPX4 and TXNRD1, ferrostatin-1 rescue experiments\",\n      \"pmids\": [\"37087975\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In-cell target engagement ratio (GPX4 vs. TXNRD1) not quantified\", \"Whether downstream ferroptotic phenotypes are TXNRD1-dependent not fully resolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"TXNRD1 inhibition was linked to a novel cell death modality—disulfidptosis—in osteoclast precursors: NFATc1-driven SLC7A11 upregulation during osteoclastogenesis creates dependence on TXNRD1 for intracellular disulfide reduction, and TXNRD1 inhibition causes lethal cystine accumulation.\",\n      \"evidence\": \"Pharmacological TXNRD1 inhibition with selective death pathway inhibitors, SLC7A11 inhibitor rescue, NFATc1 transcriptional assays, OVX mouse model\",\n      \"pmids\": [\"37148740\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TXNRD1 directly reduces cystine or acts via Trx1 not resolved\", \"Generalizability of disulfidptosis mechanism to other SLC7A11-high cell types not tested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"A non-enzymatic, protein-interaction function of TXNRD1 was discovered: TXNRD1 localizes to cytoplasmic chromatin fragments in senescent cells, physically interacts with cGAS, enhances cGAS enzymatic activity, and drives the SASP and inflammaging through cGAS-STING signaling independently of TrxR1 reductase activity.\",\n      \"evidence\": \"Reciprocal Co-IP, subcellular fractionation, cGAS activity assays, enzymatic-vs-interaction-selective inhibitors, multiple mouse models\",\n      \"pmids\": [\"38267705\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for TXNRD1-cGAS interaction not resolved\", \"Which TXNRD1 domain mediates cGAS binding unknown\", \"Whether this interaction occurs in non-senescent inflammatory contexts not tested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"TXNRD1 protein stability was shown to be regulated by TRIM25-mediated ubiquitination scaffolded by lncRNA CARD8-AS1, adding a post-translational degradation mechanism to the regulatory landscape of TXNRD1 abundance.\",\n      \"evidence\": \"RNA pull-down, Co-IP, ubiquitination assays, rescue with TXNRD1 overexpression in lung adenocarcinoma models\",\n      \"pmids\": [\"38153696\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"TRIM25 ubiquitination sites on TXNRD1 not mapped\", \"Whether this mechanism operates outside lung adenocarcinoma not tested\", \"Single-lab finding awaiting independent confirmation\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the structural basis for TXNRD1's non-enzymatic interaction with cGAS; whether the SecTRAP pro-oxidant form of TrxR1 has physiological signaling roles; how TXNRD1 isoform-specific functions (v3 membrane raft signaling, cytosolic redox catalysis) are coordinated in vivo; and whether TXNRD1 loss-of-function mutations cause a broader clinical spectrum beyond the single reported family.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal structure of TXNRD1-cGAS complex\", \"SecTRAP physiological relevance untested\", \"Full disease spectrum of TXNRD1 deficiency undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [2, 3, 4, 8, 12, 16, 18, 25]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [2, 23]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [10, 23]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [2, 4, 6, 7, 17, 19]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 14]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [17, 24, 28]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [6, 7, 15]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"TXN\",\n      \"CGAS\",\n      \"PTEN\",\n      \"TRIM25\",\n      \"PRDX2\",\n      \"GSR\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}